Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
At least 50 different venture investors have benefited from Eli Lilly’s dealmaking this year, sending early investment dollars back into the startup ecosystem.
On Monday …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Eli Lilly made 11 biotech acquisitions in H1 2026, dominating the industry's M&A total while targeting vaccines, CAR-T, ADCs &…
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an…
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.
Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious…
It’s the latest in a string of deals for Lilly, which has sunk more than $18 billion into acquisitions over the past few years.
